Protalix BioTherapeutics, Inc. (PLX)

ASE – Real Time Price. Currency in USD

1.91

-0.03 (-1.55%)

At close: May 12, 2026, 4:00 PM EDT

1.98

+0.08 (4.10%)

Pre-market: May 13, 2026, 8:08 AM EDT

06.05.2026

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026.

24.03.2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contribution is expected to exceed 50% revenue growth in 2026, improving margin mix and earnings predictability despite near-term volatility.

18.03.2026

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

18.03.2026

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress for Protalix, marked by strong commercial execution with our partners and important advances and strategic direction across our clinical and preclinical pipeline," the company's CEO Dror Bashan said.

18.03.2026

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease providing a meaningful reduction in treatment burden without compromising efficacy The EC approval triggered the Company's entitlement to a $25.0 million milestone payment from Chiesi, strengthening the Company's cash position and supporting an expected cash balance of approximately $50.0 million by April 2026 Based on current estimates, management expects total revenues in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million payment referenced above The Phase 2 clinical trial of PRX–115 is actively enrolling; the Company believes PRX-115 has the potential to be a best-in-class therapy, improving uncontrolled gout patients' compliance and outcomes Continued strategic focus on rare renal diseases to build a pipeline through innovation and partnerships CARMIEL, Israel, March 18, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the fiscal year ended December 31, 2025, and provided a business and clinical update.

09.03.2026

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for adults with Fabry disease who are stable on enzyme replacement therapy (ERT), triggering a $25 million regulatory milestone payment from partner Chiesi Global Rare Diseases. The approval allows eligible patients to receive the therapy at a dose of 2 mg/kg every four weeks, instead of the previous every-two-weeks schedule.

09.03.2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approved dosing regimen remains 1mg/kg every 2 weeks. Please see Important Safety Information below and the Full Prescribing Information , including Boxed Warning.

Videos

No Data

There is no data to display

Press releases

18.03.2026

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

09.03.2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

30.01.2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026

30.01.2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Protalix BioTherapeutics, Inc. (PLX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Videos

No Data

Press releases

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Videos

No Data

Press releases

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Search stocks

Protalix BioTherapeutics, Inc. (PLX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Videos

No Data

Press releases

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Videos

No Data

Press releases

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU